Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria
Improving Proteinuria With Sparsentan (SPAR) in Patients With IgA Nephropathy (IgAN): A Case Series
National Kidney Foundation (NKF) Spring Clinical Meetings 2025
April 10 - 13, 2025
Boston
Sparsentan in Combination With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With IgA Nephropathy (IgAN): A Case Series
Sparsentan in Patients With Prior or Concurrent Immunosuppressive Treatment (IST) for IgA Nephropathy (IgAN): A Case Series
The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Immunoglobulin A Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study (HONUS): Results for IgAN and FSGS in Europe
Natural History of Idiopathic Nephrotic Syndrome: The UK National RaDaR Idiopathic Nephrotic Syndrome Cohort
American Society of Nephrology (ASN) Kidney Week 2024
October 23 - 27, 2024
CA
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
Effects of Proteinuria Reduction on Delay of Kidney Failure in Patients With Immunoglobulin A Nephropathy
Kidney Failure Events, Cardiovascular Disease Events, and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database
Rate of Loss of eGFR and Time-Averaged Proteinuria in IgAN Patients Progressing From Early Stage Disease to Kidney Failure
Proteinuria and kidney survival in focal segmental glomerulosclerosis (FSGS) or immunoglobulin A nephropathy (IgAN): A NEPTUNE analysis